Clinical Trials

Vertex aims for broad kidney disease label ahead of key readout next year

Endpoints News 1d ago

Vertex Pharmaceuticals reported that an experimental kidney disease drug called inaxaplin improved measures on a urine test in two different patient populations, raising optimism ahead of the company’s upcoming pivotal readout. ...

Discussion

Sign in to join the discussion. Comments loading…